RxDoctor Payments Data

Erin Dills

Family · Wilmington, NCNPI 1437343357

Payments from drug & device makers

$513in general payments, 2019–2025

Across 32 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$147
  • AbbVie$71
  • Abbott$65
  • Amgen$34
  • Teva Pharmaceuticals USA, Inc.$30
  • GSK$26
  • plus $139 from 9 others

What the payments were for

  • Food & beverage$513100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$513 in reported general payments places this provider in the 55th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,757
Medicare patients
214
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide41$51,270
OzempicSemaglutide35$48,938
XifaxanRifaximin12$43,050
TrulicityDulaglutide18$27,842
EliquisApixaban32$22,980
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,660
JardianceEmpagliflozin17$19,150
ViberziEluxadoline11$16,938
Repatha SyringeEvolocumab24$14,714
XareltoRivaroxaban16$14,016
Repatha SureclickEvolocumab20$13,239
MyrbetriqMirabegron19$10,879
FarxigaDapagliflozin Propanediol12$8,934
MotegrityPrucalopride Succinate12$5,942
ZypitamagPitavastatin Magnesium16$4,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$48,93835 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$14$43,05012 claims
GSKTrelegy Ellipta$26$20,66027 claims
AbbVieViberzi, Synthroid$71$18,35229 claims
Astellas Pharma US IncMyrbetriq$16$10,87919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,522 family providers in North Carolina.

Other family in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →